Capital Advisors Ltd’s XBiotech XBIT Stock Holding History

Capital Advisors Ltd’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-209	Closed	-$1K	–	1698
2022 Q3	$1K	Buy	+209	New	+$984	﹤0.01%	1161

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Capital Advisors Ltd's XBIT Position: Q4 2022 in Review

Capital Advisors Ltd sold out of XBiotech (XBIT) in Q4 2022, closing a stake of 209 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in XBIT in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2022.

Capital Advisors Ltd reported no remaining XBiotech position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 209 XBiotech shares in Q4 2022, an estimated $1K.
Capital Advisors Ltd first reported a position in XBiotech in Q3 2022 and held it in 1 quarter.
Capital Advisors Ltd's XBiotech position peaked at $1K in Q3 2022.
41 funds tracked by Wall St. Rank held XBiotech as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.